Photo by nci from unsplash
Although dipeptidyl-peptidase-4 inhibitors (DPP4i) are one of the most popular antidiabetic agents worldwide, major randomized trials of DPP4i have failed to demonstrate the benefit of DPP4i to reduce the risk… Click to show full abstract
Although dipeptidyl-peptidase-4 inhibitors (DPP4i) are one of the most popular antidiabetic agents worldwide, major randomized trials of DPP4i have failed to demonstrate the benefit of DPP4i to reduce the risk of adverse cardiovascular events in secondary prevention. This retrospective analysis
Keywords:
peptidase inhibitors;
adverse cardiovascular;
risk adverse;
dipeptidyl peptidase;
cardiovascular events
Journal Title: Journal of the American College of Cardiology
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Journal of the American College of Cardiology
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!